IDEAYA Biosciences, Inc. is a precision medicine oncology company. The Company is engaged in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 / GSK959 (Werner Helicase), IDE161 (PARG), and IDE705 / GSK101 (Pol Theta Helicase). IDE196, a small-molecule protein kinase C (PKC) inhibitor, in combination with crizotinib, an investigational cMET inhibitor. IDE397 is its small-molecule methionine adenosyltransferase 2a (MAT2A) inhibitor. IDE275 (GSK959) Werner Helicase (WRN) inhibitor for patients having tumors with MSI-High. IDE161 (PARG) is a small-molecule poly (ADP-ribose) glycohydrolase, or PARG, inhibitor. IDE705 is a small-molecule inhibitor of Pol Theta Helicase, in combination with niraparib, the GSK small-molecule inhibitor of poly-(ADP-ribose) polymerase (PARP).
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļIDYA
āļāļ·āđāļāļāļĢāļīāļĐāļąāļIDEAYA Biosciences Inc
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļMay 23, 2019
āļāļĩāļāļĩāđāļHata (Yujiro S)
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ131
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒOrdinary Share
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļMay 23
āļāļĩāđāļāļĒāļđāđ7000 Shoreline Ct, Suite 350
āđāļĄāļ·āļāļSOUTH SAN FRANCISCO
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNASDAQ OMX - NASDAQ BASIC
āļāļĢāļ°āđāļāļĻUnited States of America
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđ94080
āđāļāļĢāļĻāļąāļāļāđ16504436209
āđāļ§āđāļāđāļāļāđhttps://www.ideayabio.com/
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļIDYA
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļMay 23, 2019
āļāļĩāļāļĩāđāļHata (Yujiro S)
Dr. Joshua Bleharski, Ph.D.
Dr. Joshua Bleharski, Ph.D.
Chief Financial Officer
Dr. Catherine J. Mackey, Ph.D.
Dr. Catherine J. Mackey, Ph.D.
Independent Director
Dr. M. Garret Hampton, Ph.D.
Dr. M. Garret Hampton, Ph.D.
Independent Director
Dr. Terry J. Rosen, Ph.D.
Dr. Terry J. Rosen, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
Dr. Darrin Beaupre, M.D., Ph.D.
Dr. Darrin Beaupre, M.D., Ph.D.
Chief Medical Officer
Dr. Jeffrey L. (Jeff) Stein, Ph.D.
Dr. Jeffrey L. (Jeff) Stein, Ph.D.
Independent Director
Mr. Andres Ruiz Briseno, CPA
Mr. Andres Ruiz Briseno, CPA
Chief Accounting Officer, Senior Vice President, Head - Finance and Investor Relations
Chief Accounting Officer, Senior Vice President, Head - Finance and Investor Relations
Dr. Michael A. White, Ph.D.
Dr. Michael A. White, Ph.D.
Chief Scientific Officer
Ms. Wendy L. Yarno
Independent Director
Mr. Yujiro S. Hata
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Dr. Joshua Bleharski, Ph.D.
Dr. Joshua Bleharski, Ph.D.
Chief Financial Officer
Dr. Catherine J. Mackey, Ph.D.
Dr. Catherine J. Mackey, Ph.D.
Independent Director
Dr. M. Garret Hampton, Ph.D.
Dr. M. Garret Hampton, Ph.D.
Independent Director
Dr. Terry J. Rosen, Ph.D.
Dr. Terry J. Rosen, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
Dr. Darrin Beaupre, M.D., Ph.D.
Dr. Darrin Beaupre, M.D., Ph.D.
Chief Medical Officer
Dr. Jeffrey L. (Jeff) Stein, Ph.D.
Dr. Jeffrey L. (Jeff) Stein, Ph.D.
Independent Director
ALPS Medical Breakthroughs ETF
Virtus LifeSci Biotech Clinical Trials ETF
Invesco Dorsey Wright Healthcare Momentum ETF
State Street SPDR S&P Biotech ETF
First Trust Innovation Leaders ETF
Direxion Daily S&P Biotech Bull 3X Shares
ProShares Ultra Nasdaq Biotechnology
Avantis US Small Cap Equity ETF
Invesco Nasdaq Biotechnology ETF
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Tema Oncology ETF
āļŠāļąāļāļŠāđāļ§āļ3.49%
ALPS Medical Breakthroughs ETF
āļŠāļąāļāļŠāđāļ§āļ1.16%
Virtus LifeSci Biotech Clinical Trials ETF
āļŠāļąāļāļŠāđāļ§āļ0.97%
Invesco Dorsey Wright Healthcare Momentum ETF
āļŠāļąāļāļŠāđāļ§āļ0.83%
State Street SPDR S&P Biotech ETF
āļŠāļąāļāļŠāđāļ§āļ0.72%
First Trust Innovation Leaders ETF
āļŠāļąāļāļŠāđāļ§āļ0.7%
Direxion Daily S&P Biotech Bull 3X Shares
āļŠāļąāļāļŠāđāļ§āļ0.45%
ProShares Ultra Nasdaq Biotechnology
āļŠāļąāļāļŠāđāļ§āļ0.38%
Avantis US Small Cap Equity ETF
āļŠāļąāļāļŠāđāļ§āļ0.29%
Invesco Nasdaq Biotechnology ETF
āļŠāļąāļāļŠāđāļ§āļ0.27%
āļĄāļĩāļāļēāļĢāļāđāļēāļĒāđāļāļīāļāļāļąāļāļāļĨāđāļāđāļāļāļģāļāļ§āļāļĢāļ§āļĄ
0.00
USD āđāļāļāđāļ§āļ 5 āļāļĩāļāļĩāđāļāđāļēāļāļĄāļē

āđāļĄāđāļĄāļĩāļāđāļāļĄāļđāļĨ